Over the past years, we have developed a new class of MC1R-targeted peptide radiopharmaceuticals that include the core structure of Gly-Gly-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH2 (GGNle-CycMSHhex) for melanoma imaging and therapy [11,12,13,14,15,16,17,18,19,20]. Here, MC1R is linked to melanoma.